Stock analysis, AI verdict, fundamentals & technical signals
Rating: SELL
Price: $70.13 Analyst target: $55.53 Upside: -20.82%
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
See the full interactive analysis & chart →Informational only — not investment advice.